Dapagliflozin ( DrugBank: Dapagliflozin )

7 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
19	ライソゾーム病	1
49	全身性エリテマトーデス	1
66	IgA腎症	1
67	多発性嚢胞腎	1
86	肺動脈性肺高血圧症	2
88	慢性血栓塞栓性肺高血圧症	2
222	一次性ネフローゼ症候群	1

19. ライソゾーム病

臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05710367 (ClinicalTrials.gov)	August 2023	10/1/2023	Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients	Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients; A Prospective, Randomized, Double-Blind, Placebo- Controlled Study.	Fabry Disease	Drug: Dapagliflozin 10mg Tab;Drug: Placebo	Albina Nowak, MD	NULL	Not yet recruiting	18 Years	70 Years	All	46	Phase 2	NULL

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1800015030	2018-03-01	2018-03-01	A Clinical Trial on Safety and effect of Dapagliflozin to Control Blood Glucose Levels in Systemic Lupus Erythematosus	The Safety of SGLT2-i Dapagliflozin on Treating Blood Glucose Levels in SLE	Systemic Lupus Erythematosus	Case series:add-on or replace dapagliflozin;	Dept. Rheumatology, Renji Hospital South Campus	NULL	Pending	18	70	Both	Case series:35;	4 (Phase 4 study)	China

66. IgA腎症

臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03762850 (ClinicalTrials.gov)	December 11, 2018	27/11/2018	A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy	A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy	Immunoglobulin A Nephropathy	Drug: sparsentan;Drug: irbesartan;Drug: Dapagliflozin	Travere Therapeutics, Inc.	NULL	Active, not recruiting	18 Years	N/A	All	380	Phase 3	United States;Australia;Belgium;Croatia;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom

67. 多発性嚢胞腎

臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000046275	2021/12/11	06/12/2021	The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan: randomized crossover controlled trial	The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan: randomized crossover controlled trial - The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan	Autosomal dominant polycystic kidney disease (ADPKD)	Dapagliflozin 10mg/day for 6 months No treatment for 6 months	Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine	Department of Nephrology, International University of Health and Welfare School of MedicineDivision of Nephrology, Japanese Red Cross Medical Center	Recruiting	20years-old	Not applicable	Male and Female	30	Not selected	Japan

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05179356 (ClinicalTrials.gov)	January 1, 2023	16/12/2021	Dapagliflozin in Pulmonary Arterial Hypertension	Effects of DAPAgliflozin on Cardiopulmonary Exercise Capacity and Hemodynamics in Pulmonary Arterial Hypertension: A Double Blind Randomized Trial. (DAPAH-trial)	Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension	Drug: Dapagliflozin 10 MG [Farxiga];Drug: Placebo	Mads Ersbøll	NULL	Not yet recruiting	18 Years	N/A	All	52	Phase 2	NULL
2	EUCTR2021-006787-25-DK (EUCTR)	06/07/2022	22/12/2021	The effects of dapagliflozin in patients with elevated blood pressure in the lungs	Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial	Pulmonary arterial hypertensionChronic thromboembolic pulmonary hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 21.1;Classification code 10065151;Term: Idiopathic pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 24.1;Classification code 10085244;Term: Heritable pulmonary arterial hypertension;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 21.0;Classification code 10068740;Term: CTEPH;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Forxiga (dapagliflozin) Product Name: Forxiga INN or Proposed INN: Dapagliflozin	Rigshospitalet The Heart Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 2	Denmark

88. 慢性血栓塞栓性肺高血圧症

臨床試験数 : 157 / 薬物数 : 107 - (DrugBank : 22) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 54

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05179356 (ClinicalTrials.gov)	January 1, 2023	16/12/2021	Dapagliflozin in Pulmonary Arterial Hypertension	Effects of DAPAgliflozin on Cardiopulmonary Exercise Capacity and Hemodynamics in Pulmonary Arterial Hypertension: A Double Blind Randomized Trial. (DAPAH-trial)	Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension	Drug: Dapagliflozin 10 MG [Farxiga];Drug: Placebo	Mads Ersbøll	NULL	Not yet recruiting	18 Years	N/A	All	52	Phase 2	NULL
2	EUCTR2021-006787-25-DK (EUCTR)	06/07/2022	22/12/2021	The effects of dapagliflozin in patients with elevated blood pressure in the lungs	Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial	Pulmonary arterial hypertensionChronic thromboembolic pulmonary hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 21.1;Classification code 10065151;Term: Idiopathic pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 24.1;Classification code 10085244;Term: Heritable pulmonary arterial hypertension;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 21.0;Classification code 10068740;Term: CTEPH;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Forxiga (dapagliflozin) Product Name: Forxiga INN or Proposed INN: Dapagliflozin	Rigshospitalet The Heart Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 2	Denmark

222. 一次性ネフローゼ症候群

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02585804 (ClinicalTrials.gov)	September 2015	22/10/2015	Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects	Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: The TRANSLATE Study	Focal Segmental Glomerulosclerosis	Drug: Dapagliflozin	University Health Network, Toronto	AstraZeneca;University of Toronto;Toronto General Hospital	Completed	18 Years	N/A	All	10	Phase 4	Canada

先頭へ